WO2004022553A1 - INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE - Google Patents
INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE Download PDFInfo
- Publication number
- WO2004022553A1 WO2004022553A1 PCT/EP2003/008629 EP0308629W WO2004022553A1 WO 2004022553 A1 WO2004022553 A1 WO 2004022553A1 EP 0308629 W EP0308629 W EP 0308629W WO 2004022553 A1 WO2004022553 A1 WO 2004022553A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- pyrimidin
- indole
- formula
- Prior art date
Links
- UNCQVRBWJWWJBF-UHFFFAOYSA-N Clc1ncccn1 Chemical compound Clc1ncccn1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N c(cc1)ccc1Nc1ncccn1 Chemical compound c(cc1)ccc1Nc1ncccn1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the invention relates to indole or benzimidazole derivatives which inhibit I ⁇ B kinase, to processes for their preparation and their use as medicaments.
- NFKB is a heterodimeric transcription factor that can activate a variety of genes, including but not limited to, proinflammatory cytokines such as IL-1, IL-2, TNF ⁇ or IL-6.
- NFKB is present in the cytosol of cells complexed with its naturally occurring inhibitor IKB.
- NFKB is activated beyond normal levels and inhibition of NFKB is also involved in the treatment of cancer It can be shown that drugs such as glucocorticoids, salicylates or gold salts used in rheumatism intervene at different sites in the NFKB activating signaling pathway or directly with the Transcription of genes interfere.
- the first step in the mentioned signal cascade is the removal of IKB.
- This phosphorylation is regulated by the specific IkB kinase.
- So far no inhibitors are known which specifically inhibit IkB kinase.
- Disadvantage of the known inhibitors of IkB kinase is often the lack of specificity of the inhibition for only one class of kinases.
- most inhibitors of IkB kinase inhibit several different kinases simultaneously because the catalytic domains of these kinases have similar structures.
- the inhibitors undesirably act on many enzymes, including those of vital function.
- Benzimidazole derivatives are potent inhibitors of IkB kinase, thereby very selectively inhibiting kinases and have a high blood plasma level after oral administration.
- the invention therefore relates to the compound of the formula
- X and M are the same or different and independently of one another represent N atom or CH,
- R1 and R11 are the same or different and independently of one another
- R 5 and R 6 independently of one another represent hydrogen or - ( C 1 -C 4) -alkyl, 8 -C (0) -R 5 , wherein R 5 represents hydrogen atom or - (C 1 -C 4) alkyl, or
- R 2 for 1. a heteroaryl radical from the group 3-hydroxypyrro-2,4-dione, imidazole, imidazolidine, imidazoline, indazole, isothiazole, isothiazolidine, isoxazole, 2-isoxazolidine,
- R 5 is hydrogen atom or - (G 1 -C 4) -alkyl
- R 7 and independently of one another represent hydrogen, - (C 1 -C 4 -alkyl-OH, -O- (C 1 -C 4) -alkyl or - (C-) -C4) -alkyl,
- R 3 is hydrogen or - (C 1 -C 4) -alkyl
- R4 represents a heteroaryl radical from the group pyrrole, furan, thiophene, imidazole, JPyrazol, oxazole, isoxazole, thiazole, isothiazole, tetrazole, 1,2,3,5-oxathiadiazole-2-oxides, triazolones, oxadiazolone, isoxazolone, oxadiazolidinedione , Triazole, 3-hydroxypyrro-2,4-diones, 5-oxo-1,2-thiadiazoles, pyridine, pyrazine, pyrimidine,
- Halogen nitro, amino, trifluoromethyl, hydroxyl, hydroxy (O-C4) -alkyl,
- an aryl radical from the group consisting of phenyl, naphthyl, 1-naphthyl, 2-naphthyl, biphenylyl, 2-biphenylyl, 3-biphenylyl and 4-biphenylyl, anthryl or fluorenyl, and the aryl radical is unsubstituted or mono-, di- or is substituted independently of one another by - (G] -C5) -alkyl, - (C -] -C5) -alkoxy, halogen, nitro,
- the invention furthermore relates to compounds of the formula I in which 5 and M are identical or different and independently of one another represent an N atom or CH, R 1 and R 11 are as defined above under 1 to 9, R 2 is 1. a heteroaryl radical imidazole, isothiazole, isoxazole, 2-
- R 3 is hydrogen, methyl or ethyl
- R4 represents 1. a heteroaryl radical from the group of unsaturated, partially saturated or completely saturated rings, which is derived from pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole or Derive isothiazole, wherein the heteroaryl radical is unsubstituted or mono-, di- or trisubstituted
- phenyl is unsubstituted or phenyl is mono-, di- or trisubstituted independently of one another by F, Cl, J, Br, CF3, -OH, - (C1-C4) -
- the invention further relates to the compound
- Carbon chain is straight or branched and contains 1 to 5 carbon atoms such as methyl, ethyl, propyl, n-butyl, pentyl or tert-butyl.
- heteroaryl radical from the group of unsaturated, partially saturated or fully saturated rings derived from pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole for example Compounds such as piperazine, pyrazoline, imidazoline, pyrazolidine, imidazolidine, tetrahydropyridine, isoxazoline, isoxazolidine, morpholine, isothiazoline, isothiazolidine, tetrahydro-1,4-thiazine or piperidine. - - --- -. - - -
- the compounds of the formula I are prepared, for example, as described in the patent applications WO 01/00610 and WO 01/30774.
- the starting materials of the chemical reactions are known or can be easily prepared by literature methods.
- the invention further relates to a process for the preparation of the compound of the formula I and / or a stereoisomeric form of the compound of the formula I and / or a physiologically acceptable salt of the compound of the formula I which is characterized in that a) a compound of the formula IV,
- R1 wherein R1, R2 and R4 are as defined in formula I, with an acid chloride or an activated ester of the compound of formula III,
- D1 is -C00H and R11, X, M and R3 are as defined in formula I, in the presence of a base or optionally a dehydrating agent in solution and converted into a compound of formula I, b) a compound prepared according to process a) of the formula I, which occurs in enantiomeric forms due to their chemical structure, by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds such as amino acids, separation of the diastereomers thus obtained, and cleavage of the chiral auxiliary groups in the pure enantiomers or c) the compound of the formula I prepared according to process a) or b). .... , either isolated in free form or converted into physiologically acceptable salts in the presence of acidic or basic groups.
- the preparation of the indole or benzimidazolecarboxylic acid derivatives is carried out by a method as described in Houben-Weyl "Methoden der Org. Chemie", Vol. E6-2A or E6-2B.
- hydrazinobenzoic acids and aryl or heteroaryl ketones in the presence of polyphosphoric acid as the solvent at 145.degree. C., can be used to prepare the indole or benzimidazolecarboxylic acid derivatives of the formula III.
- the preparation of the required hydrazinobenzoic acids is carried out by methods familiar to the person skilled in the art, e.g. from the corresponding benzoic acid anilines, aryl or heteroaryl ketones are also methods commonly used in the art z. B. from the corresponding acid chlorides or nitriles by reaction with e.g. Organometallic compounds produced.
- condensing agents or coupling reagents are compounds such as carbonyldiimidazole, carbodiimide such as dicyclohexylcarbodiimide or diisopropylcarbodiimide (DIC), the 0 - ((cyano (ethoxycarbonyl) methylene) amino) -N, N, N ', N'-tetramethyluronium tetrafluoroborate (TOTU ) or propylphosphonic anhydride (PPA).
- the condensations can be carried out under standard conditions. In the condensation, it is usually necessary that the existing, non-reactive amino groups are protected by reversible protecting groups. The same applies to non-participating in the reaction carboxyl groups, the.
- the - (G-C ⁇ ) - alkyl ester, benzyl ester or tert-butyl ester preferably present as the - (G-C ⁇ ) - alkyl ester, benzyl ester or tert-butyl ester during the condensation.
- An amino group protection is unnecessary if the amino groups are still present in the form of precursors such as nitro groups or cyano groups and are formed only after the condensation by hydrogenation.
- the protective groups present are split off in a suitable manner. For example, N0 groups (guanidino protection in amino acids), benzyloxycarbonylgrups and benzyl groups in benzyl esters can be hydrogenated off.
- the tert-butyl type protecting groups are acid-cleaved while the 9-fluorenylmethyloxycarbonyl residue is removed by secondary amines.
- the invention also relates to pharmaceutical compositions, characterized by an effective content of at least one compound of formula I and / or a physiologically acceptable salt of the compound of formula I and / or an optionally stereoisomeric form of the compound of formula I, together with a pharmaceutically acceptable and physiological compatible carrier, additive and / or other active ingredients and excipients.
- Compounds for the prophylaxis and therapy of all such diseases, in the course of which an increased activity of IkB kinase is involved include, for example, chronic musculoskeletal disorders such as inflammatory, immunological or metabolic acute and chronic arthritides, arthropathies, rheumatoid arthritis, or degenerative joint diseases such as osteoarthritis, spondylosis, type II diabetes, inflammatory bowel disease, cartilage shrinkage after joint trauma, or prolonged joint restraint after meniscal dislocation.
- chronic musculoskeletal disorders such as inflammatory, immunological or metabolic acute and chronic arthritides, arthropathies, rheumatoid arthritis, or degenerative joint diseases such as osteoarthritis, spondylosis, type II diabetes, inflammatory bowel disease, cartilage shrinkage after joint trauma, or prolonged joint restraint after meniscal dislocation.
- TNF ⁇ tumor necrosis factor alpha
- diseases due to overexpression of tumor necrosis factor alpha (TNF ⁇ ) or increased levels of TNF ⁇ such as cachexia, multiple sclerosis, craniocerebral Trauma, Crohn's disease and intestinal ulcers, or diseases such as atherosclerosis, stenosis, ulceration, Alzheimers diseases, Muscle breakdown, cancers (potentiation of cytotoxic therapies), myocardial infarction, gout, sepsis, septic shock, endotoxic shock, viral infections such as influenza, hepatitis, HIV infections, AIDS, or adenoviruses or herpesvirus-induced diseases, parasitic infections such as malaria or leprosy , Fungal or yeast infections, meningitis, chronic inflammatory lung diseases such as chronic bronchitis or asthma, acute respiratory distress syndrome, acute synovitis, tuberculosis, psorias
- the application of the medicaments according to the invention can be effected by oral, inhalative, rectal or transdermal administration or by subcutaneous, intra-articular, intraperitoneal or intravenous injection.
- the oral application is preferred.
- the invention also relates to a process for the preparation of a medicament, which comprises bringing at least one compound of the formula I into a suitable administration form with a pharmaceutically suitable and physiologically acceptable carrier and optionally further suitable active substances, additives or excipients.
- Suitable solid or galenic forms of preparation are, for example, granules, powders, dragees, tablets (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions as well as sustained-release preparations prepared by conventional means such as excipients Explosives, binders, coatings, swelling, lubricants or lubricants, flavoring agents, sweeteners and solubilizers.
- auxiliaries are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as sterile Water and mono- or polyvalent ones Alcohols such as glycerin, called.
- the pharmaceutical preparations are prepared and administered in dosage units, each unit containing as active ingredient a specific dose of the compound of formula I according to the invention.
- this dose may be up to about 1000 mg, preferably from about 50 mg to 300 mg and for injection solutions in ampoule form up to about 300 mg, preferably from about 10 mg to 100 mg , Depending on the efficacy of the compound according to formula I, daily doses of about 20 mg to 1000 mg of active ingredient, preferably about 100 mg to 500 mg, are indicated for the treatment of an adult patient weighing about 70 kg. However, higher or lower daily doses may be appropriate. Administration of the daily dose. can be done by single dose in the form of a single dosage unit or several smaller dosage units as well as by multiple subdivided doses at specific intervals.
- End products are usually determined by mass spectroscopic methods (FAß-, ESI-MS). Temperatures in degrees Celsius, RT means room temperature (22 ° C to 26 ° C). Used abbreviations are either explained or correspond to the usual conventions. The invention is explained in more detail with reference to examples.
- Empirical formula C 24 H 24 N 2 0 4 ; MW 404.47; MS (M + H) 405.2.
- the Z-protective group was split off by dissolving 2.7 g (6.68 mmol) of the Z-protected derivative (10) in 500 ml of methanol and, under a protective nitrogen atmosphere, 100 mg of catalyst (10%).
- Empirical formula C 16 H ⁇ 8 N 2 0 2 ; MW 270.32; MS (M + H) 271.2.
- racemic amino acids prepared via acrylic acid could be synthesized by preparative
- Boc-Serine (12) 50 g (0.228 mol) of Boc-Serine (12) were dissolved in 300 ml of acetonitrile. 107 g (0.493 mol) of Boc anhydride and 2.64 g (22 mmol) of DMAP were added. It was allowed to stir at RT overnight, removed
- Cesium carbonate mixed 100 ml of acetonitrile were added and allowed to stir at 55 ° C for 2 days.
- Reaction formed methanol was continuously removed from the reaction solution by distillation. After cooling, the solution was extracted with heptane and the
- Empirical formula C8H ⁇ 3 N 3 0 2 ; MW 183.21; MS (M + H) 184.1.
- Diamino-benzoic acid were heated to 150 ° C in 300 ml of nitrobenzene for 2 hours. After cooling to 0 ° C, the precipitate of the benzimidazole was separated by filtration from the nitrobenzene and the product was purified by flash chromatography (DCM / methanol 4: 1). Yield:
- Empirical formula C 30 H 2 6N 8 O 3 ; MW 546.6; MS (M + H) 547.3.
- the solvent was i. V. and the residue between 100 ml of saturated (sat.) NaHC0 3 solution and 100 ml of ethyl acetate distributed.
- the aqueous phase was extracted 3 times with 50 ml of ethyl acetate and the combined organic phases washed with 100 ml of saturated NaCl solution.
- the organic phase was dried with magnesium sulfate.
- the solvents were i. V. and the residue chromatographed on silica gel with heptane / ethyl acetate 1: 3. 560 mg (68%) of the ester 29 were obtained.
- Molecular Formula C 29 H 26 FN 7 0 3 ; MW 539.57; MS (M + H) 540.2.
- the mixture was stirred for 12 h at RT.
- the solvent was i. V. removed and the residue between 300 ml sat. NaHC0 3 solution and 300 ml of ethyl acetate.
- the aqueous phase was extracted 3 times with 100 ml of ethyl acetate and the combined organic phases with 400 ml of sat. NaCl solution washed.
- the organic phase was dried with magnesium sulfate.
- the solvents were i. V. and the residue chromatographed on silica gel with heptane / ethyl acetate 1: 3. 1.78 g (55%) of the ester 32 were obtained.
- Molecular Formula C 29 H 2 7N 7 0 3 ; MW 521.58; MS (M + H) 522.2.
- Empirical formula C 28 H 24 FN 7 0 3 ; MW 525.55; MS (M + H) 526.2.
- Empirical formula C 27 H 23 FN 8 0 2 ; MW 510.54; MS (M + H) 511.2.
- Empirical formula C 29 H 2 8N 8 0 3 ; MW 536.60; MS (M + H) 537.2.
- 1 H NMR (DMSO-de) 2.95 (s, 3H), 3.52 (s, 3H), 4.09-4.18 (m, 1H), 5.51-4.62 (m, 2H), 6.33 (d, 1H )
- Empirical formula C 2 8H 26 N 8 0 3 ; MW 522.57; MS (M + H) 523.3.
- Empirical formula C 2 8H 2 eFN 9 ⁇ 2 ; MW 539.58; MS (M + H) 540.2.
- l ⁇ B Kinase ELISA The activity of the l ⁇ B kinase was determined by an ELISA consisting of a biotinylated substrate peptide containing the amino acid sequence in the protein IKB of serine 32 to 36 and a specific poly- or monoclonal antibody (eg from New England Biolabs, Beverly, MA, USA, cat .: 9240), which binds only to the phosphorylated form of the peptide IKB.
- This complex was coated on an antibody-binding plate (protein A) immobilized and detected with a conjugate of a biotin-binding protein and HRP (eg Streptävidin-HRP). The activity was quantified using a standard substrate phosphopeptide curve.
- test substances (2 ⁇ l) dissolved in DMSO were incubated for 30 minutes at 25 ° C. with 43 ⁇ l of activated enzyme (diluted 1:25 in reaction buffer 50 mm HEPES, pH 7.5, 10 mm MgCk, 5 mm DTT, 10 mm ⁇ -glycerophosphate , 2.5 ⁇ M microcystin-LR) preincubated. Then 5 ⁇ l substrate peptide (biotin (CH 2 ) e-DRHDSGLDSMKD-CONH 2 ) (200 ⁇ M) were added, incubated for one hour and washed with 150 ⁇ l 50 mm HEPES pH 7.5, 0.1% BSA, 50 mm EDTA, antibody [ 1: 200] stopped.
- activated enzyme diluted 1:25 in reaction buffer 50 mm HEPES, pH 7.5, 10 mm MgCk, 5 mm DTT, 10 mm ⁇ -glycerophosphate , 2.5 ⁇ M microcystin-LR
- TMB substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) was added and color development was stopped by addition of 100 ⁇ L 0.18 M sulfuric acid. The absorbance was measured at 450 nm. The standard curve was generated by linear regression according to a 4-parameter dose-response relationship. On Using this standard curve, the enzyme activity or its inhibition by the test substances was quantified.
- the IC50 for 2- (2-methylamine-pyrimidin-4-yl) -1H-indole-5-carboxylic acid [(S) -2-diphenylamine-1- (5-oxo-4,5-dihydro- [1,3 , 4] oxadiazol-2-yl) -ethyl] -amide was 0.050 ⁇ M.
- compound 28 was administered to male C57 / BL6 mice.
- about 25 mg of the compound 28 per kg body weight of the mice were wet-ground in 0.5% hydroxyethyl cellulose (HEC) as a suspension given orally (via gavage).
- HEC hydroxyethyl cellulose
- the blood samples were drawn after 0.25; 0.5; 1; 2; 4; 6 and 8 hours (killing blood was taken from each of 2 animals at each of the mentioned times).
- the blood samples were converted to heparin plasma.
- the plasma samples were stored at -20 ° C until analysis. Analysis: The plasma samples were thawed. Subsequently, the plasma proteins interfering with the analysis were eye-precipitated by means of acetonitrile.
- the plasma level of compound 13 was determined by LC-MS / MS according to the following method: HPLC system: Agilent 1100 Software: Analyst
- the lower detection limit of the method is 0.01 ⁇ g / mL.
- the ICsg value in the kinase enzyme protein tyrosine kinase was determined.
- the protein tyrosine kinase activity was measured using the appropriate test kit from Upstate
- the test substance was tested in duplicate.
- the ICso calculations were performed with the software package GraFit 3.0.
- the IC50 for 2- (2-methylamine-pyrimidin-4-yl) -1H-indole-5-carboxylic acid [(S) -2-diphenylamine-1- (5-oxo-4,5-dihydro- [1,3 , 4] oxadiazol-2-yl) -ethyl] -amide (compound 28) was in
- the comparative compound was prepared as described in WO 01/30774 and is referred to below as a comparative compound.
- the comparative compound was administered to male NMRI mice. In each case about 50 mg of the comparative compound per kg of body weight of the mice in 0.5% HEC as a suspension were given orally (via gavage).
- the blood samples were drawn after 0.25; 0.5; 1 ; 2; 4; 6 and 8 hours (killing blood was taken from each of 2 animals at each of the mentioned times).
- the blood samples were converted to heparin plasma.
- the plasma samples were stored at -20 ° C until analysis. Analysis: The analysis was carried out with HPLC / UV.
- the plasma level content of the comparative compound was determined by means of HPLC / UV according to the following method:
- MS Device PE - Sciex API 365 (Triple Quadrupole Mass Spectrometer) Software: MacQuan Software (PE-Sciex) Detection Type: MS / MS (MRM) Flow rate: 0.5 mL / min Injection volume: 100 ⁇ L
- the lower detection limit of 0.01 ⁇ g / mL was identical to that of LC-MS / MS in Example 10 with Compound 28. , ,
- the IC50 for the reference compound was 46.35 ⁇ M in the protein tyrosine kinase assay described above. Therefore, the IC50 is significantly better than the compound 28.
- the quotient for the compound 28 is 1650 (82.5 / 0.05) and for the comparative compound 25 46.35 (46.35 / 1.0, according to the data from WO 01/30774).
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200502387A UA78591C2 (en) | 2002-08-17 | 2003-05-08 | INDOLE OR BENZIMIDAZOLE DERIVATIVE AS SUBSTANCES MODULATING IkB KINASE |
JP2004533319A JP4504812B2 (ja) | 2002-08-17 | 2003-08-05 | IκBキナーゼをモジュレートするためのインドール誘導体またはベンズイミダゾール誘導体 |
EP03793685A EP1530568B1 (de) | 2002-08-17 | 2003-08-05 | INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE |
BRPI0313562-4A BR0313562A (pt) | 2002-08-17 | 2003-08-05 | derivados de indol ou benzimidazol para a modulação da ikb-cinase |
KR1020057002707A KR101162046B1 (ko) | 2002-08-17 | 2003-08-05 | IκB 키나제 조절용 인돌 또는 벤즈이미다졸 유도체 |
AU2003263196A AU2003263196B2 (en) | 2002-08-17 | 2003-08-05 | Indole or benzimidazole derivatives for modulating IkappaB kinase |
YU20050104A RS51902B (sr) | 2002-08-17 | 2003-08-05 | Derivati indola ili benzimidazola za modulaciju ikb-kinaze |
NZ538296A NZ538296A (en) | 2002-08-17 | 2003-08-05 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase |
DE50313372T DE50313372D1 (de) | 2002-08-17 | 2003-08-05 | INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE |
MEP-606/08A MEP60608A (en) | 2002-08-17 | 2003-08-05 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE |
AT03793685T ATE493402T1 (de) | 2002-08-17 | 2003-08-05 | Indol-oder benzimidazolderivate zur modulation der ikb-kinase |
SI200331971T SI1530568T1 (sl) | 2002-08-17 | 2003-08-05 | Indolni ali benzimidazolni derivati za modulacijo IkapaB-kinaze |
DK03793685.3T DK1530568T3 (da) | 2002-08-17 | 2003-08-05 | Indol- eller benzimidazolderivater til modulering af ikb-kinasen |
CA2498559A CA2498559C (en) | 2002-08-17 | 2003-08-05 | Indole derivatives or benzimidazole derivatives for modulating i.kappa.b kinase |
MXPA05001314A MXPA05001314A (es) | 2002-08-17 | 2003-08-05 | Derivados de indol o derivados de bencimidazol para modular ikb quinasa. |
HRP20050042AA HRP20050042B1 (hr) | 2002-08-17 | 2005-01-14 | DERIVATI INDOLA ILI BENZIMIDAZOLA ZA MODULACIJU IkB KINAZE |
IL16678505A IL166785A0 (en) | 2002-08-17 | 2005-02-09 | Indole derivatives or benzimidazole derivatives for modulating ikappab kinase |
TNP2005000045A TNSN05045A1 (en) | 2002-08-17 | 2005-02-16 | Indole or benzimidazole derivatives for modulating ikappab kinase |
NO20051337A NO330981B1 (no) | 2002-08-17 | 2005-03-15 | Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene |
HK05111392A HK1079509A1 (en) | 2002-08-17 | 2005-12-12 | Indole or benzimidazole derivatives for modulating1 B kinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10237722A DE10237722A1 (de) | 2002-08-17 | 2002-08-17 | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
DE10237722.7 | 2002-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004022553A1 true WO2004022553A1 (de) | 2004-03-18 |
Family
ID=31968974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/008629 WO2004022553A1 (de) | 2002-08-17 | 2003-08-05 | INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE |
Country Status (43)
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113544A1 (en) * | 2004-05-12 | 2005-12-01 | Aventis Pharmaceuticals Inc. | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor |
WO2006005436A1 (de) * | 2004-07-10 | 2006-01-19 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur herstellung der enantiomeren formen von 2,3-diaminopropionsäurederivaten |
WO2006076318A1 (en) * | 2005-01-12 | 2006-07-20 | Aventis Pharmaceuticals Inc. | Monopotassium salt of an ikb kinase inhibitor |
WO2006128585A1 (de) * | 2005-06-01 | 2006-12-07 | Sanofi-Aventis | Verfahren zur herstellung von 2-(2-amino-pyrimidin-4-yl)-1h-indol-5-carbonsäure-derivaten |
WO2007005534A2 (en) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
WO2007043653A1 (ja) * | 2005-10-13 | 2007-04-19 | Taisho Pharmaceutical Co., Ltd. | ベンゾイミダゾール-5-カルボキサミド誘導体 |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US7858796B2 (en) | 2004-09-21 | 2010-12-28 | Glaxo Group Limited | Chemical compounds |
EP2266561A2 (de) | 2005-09-07 | 2010-12-29 | Merck Serono S.A. | IKK-Inhibitoren zur Behandlung von Endometriose |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011134140A1 (en) * | 2010-04-27 | 2011-11-03 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012019967A1 (en) | 2010-08-12 | 2012-02-16 | Sanofi | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives |
WO2012074135A1 (en) * | 2010-12-01 | 2012-06-07 | Sumitomo Chemical Company, Limited | Pyrimidine compound and use for pest control thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
WO2013027196A1 (en) * | 2011-08-25 | 2013-02-28 | St. Jude Children's Research Hospital | Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013083553A1 (en) | 2011-12-06 | 2013-06-13 | Sanofi | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
US8501780B2 (en) | 2004-06-24 | 2013-08-06 | Glaxosmithkline Llc | Indazole carboxamides and their use |
EP2805705A1 (de) | 2013-05-23 | 2014-11-26 | IP Gesellschaft für Management mbH | Verpackung enthaltend Verabreichungseinheiten von Natriumsalzen der (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-Propionsäure |
US9029334B2 (en) | 2013-03-29 | 2015-05-12 | Lifetree Biotech Co., Ltd. | Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative |
WO2016001197A1 (en) * | 2014-07-03 | 2016-01-07 | Sanofi | 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis |
US10858336B2 (en) | 2011-07-27 | 2020-12-08 | Astazeneca Ab | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
WO2021154902A1 (en) * | 2020-01-30 | 2021-08-05 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
CN115974849A (zh) * | 2022-12-28 | 2023-04-18 | 中国药科大学 | 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
US20070142417A1 (en) * | 2005-05-11 | 2007-06-21 | Aventis Pharmaceuticals Inc | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
WO2007019345A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
MX2010004965A (es) * | 2007-11-01 | 2010-05-20 | Sirtris Pharmaceuticals Inc | Derivados de amida como moduladores de la sirtuina. |
CA2705138A1 (en) * | 2007-11-08 | 2009-05-14 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
PE20120057A1 (es) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina |
KR20130130875A (ko) * | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스 억제제 |
JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
EA202092034A3 (ru) * | 2012-01-27 | 2021-02-26 | Астразенека Аб | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака |
EP2905282A1 (de) * | 2014-02-05 | 2015-08-12 | AXXAM S.p.A. | Substituierte Thiazole oder Oxazole als P2X7-Rezeptorantagonisten |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
EP3290416A1 (de) * | 2016-08-31 | 2018-03-07 | AXXAM S.p.A. | Substituierte n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- und n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- derivate und ihre verwendung als p2x7 rezeptor antagonist |
CN106588803A (zh) * | 2016-11-16 | 2017-04-26 | 西南科技大学 | 一种制备5‑乙酰基异噁唑的新方法 |
CN108299302A (zh) * | 2017-01-11 | 2018-07-20 | 西南科技大学 | 一种制备3-乙酰基吡唑的新方法 |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000610A1 (de) * | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Substituierte benzimidazole |
WO2001030774A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Deutschland Gmbh | Substituierte indole zur modulierung von nfkb-aktivität |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69327536T2 (de) | 1992-10-14 | 2000-07-06 | Merck & Co., Inc. | Fibrinogenrezeptor-antagonisten |
GB9225141D0 (en) | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
IT1275433B (it) * | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | Derivati di diarildiammine |
JP2004529088A (ja) | 2001-02-01 | 2004-09-24 | ブリストル−マイヤーズ スクイブ カンパニー | IkBキナーゼ(IKK)のインヒビターを用いる炎症性および免疫疾患の処置法 |
DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
US7462638B2 (en) * | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
US7046741B2 (en) * | 2004-04-16 | 2006-05-16 | Data Flow Technologies, Inc. | Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems |
-
2002
- 2002-08-17 DE DE10237722A patent/DE10237722A1/de not_active Withdrawn
-
2003
- 2003-05-08 UA UAA200502387A patent/UA78591C2/uk unknown
- 2003-07-23 JO JO200387A patent/JO2764B1/en active
- 2003-08-05 AU AU2003263196A patent/AU2003263196B2/en not_active Ceased
- 2003-08-05 ES ES10163200T patent/ES2387954T3/es not_active Expired - Lifetime
- 2003-08-05 RS YU20050104A patent/RS51902B/sr unknown
- 2003-08-05 ES ES03793685T patent/ES2358795T3/es not_active Expired - Lifetime
- 2003-08-05 CA CA2498559A patent/CA2498559C/en not_active Expired - Fee Related
- 2003-08-05 CN CNB038195437A patent/CN1314683C/zh not_active Expired - Fee Related
- 2003-08-05 WO PCT/EP2003/008629 patent/WO2004022553A1/de active Application Filing
- 2003-08-05 SI SI200331971T patent/SI1530568T1/sl unknown
- 2003-08-05 AT AT03793685T patent/ATE493402T1/de active
- 2003-08-05 RU RU2005107418/04A patent/RU2318820C2/ru not_active IP Right Cessation
- 2003-08-05 PT PT10163200T patent/PT2233483E/pt unknown
- 2003-08-05 EP EP10163200A patent/EP2233483B1/de not_active Expired - Lifetime
- 2003-08-05 DK DK03793685.3T patent/DK1530568T3/da active
- 2003-08-05 ME MEP-606/08A patent/MEP60608A/xx unknown
- 2003-08-05 NZ NZ538296A patent/NZ538296A/en not_active IP Right Cessation
- 2003-08-05 DE DE50313372T patent/DE50313372D1/de not_active Expired - Lifetime
- 2003-08-05 MX MXPA05001314A patent/MXPA05001314A/es active IP Right Grant
- 2003-08-05 PL PL03374229A patent/PL374229A1/xx unknown
- 2003-08-05 JP JP2004533319A patent/JP4504812B2/ja not_active Expired - Fee Related
- 2003-08-05 SI SI200332173T patent/SI2233483T1/sl unknown
- 2003-08-05 KR KR1020057002707A patent/KR101162046B1/ko not_active IP Right Cessation
- 2003-08-05 DK DK10163200.8T patent/DK2233483T3/da active
- 2003-08-05 PE PE2003000772A patent/PE20040893A1/es not_active Application Discontinuation
- 2003-08-05 AT AT10163200T patent/ATE557018T1/de active
- 2003-08-05 OA OA1200500047A patent/OA12908A/en unknown
- 2003-08-05 EP EP03793685A patent/EP1530568B1/de not_active Expired - Lifetime
- 2003-08-05 PT PT03793685T patent/PT1530568E/pt unknown
- 2003-08-05 BR BRPI0313562-4A patent/BR0313562A/pt not_active Application Discontinuation
- 2003-08-12 PA PA20038580501A patent/PA8580501A1/es unknown
- 2003-08-14 TW TW092122309A patent/TWI290552B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102946A patent/AR040975A1/es not_active Application Discontinuation
- 2003-08-15 HN HN2003000249A patent/HN2003000249A/es unknown
- 2003-08-15 MY MYPI20033115A patent/MY140074A/en unknown
- 2003-08-15 UY UY27941A patent/UY27941A1/es unknown
- 2003-08-15 SV SV2003001599A patent/SV2004001599A/es unknown
- 2003-08-18 US US10/642,970 patent/US7285560B2/en not_active Expired - Lifetime
-
2005
- 2005-01-13 ZA ZA200500322A patent/ZA200500322B/en unknown
- 2005-01-14 HR HRP20050042AA patent/HRP20050042B1/hr not_active IP Right Cessation
- 2005-01-28 CR CR7668A patent/CR7668A/es unknown
- 2005-02-09 IL IL16678505A patent/IL166785A0/xx not_active IP Right Cessation
- 2005-02-15 MA MA28106A patent/MA27382A1/fr unknown
- 2005-02-15 CO CO05013335A patent/CO5690586A2/es active IP Right Grant
- 2005-02-16 TN TNP2005000045A patent/TNSN05045A1/en unknown
- 2005-02-17 EC EC2005005612A patent/ECSP055612A/es unknown
- 2005-03-15 NO NO20051337A patent/NO330981B1/no not_active IP Right Cessation
- 2005-12-12 HK HK05111392A patent/HK1079509A1/xx not_active IP Right Cessation
-
2007
- 2007-06-06 US US11/758,978 patent/US8778955B2/en not_active Expired - Fee Related
-
2011
- 2011-03-02 CY CY20111100246T patent/CY1111692T1/el unknown
-
2012
- 2012-07-24 CY CY20121100658T patent/CY1112991T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000610A1 (de) * | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Substituierte benzimidazole |
WO2001030774A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Deutschland Gmbh | Substituierte indole zur modulierung von nfkb-aktivität |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113544A1 (en) * | 2004-05-12 | 2005-12-01 | Aventis Pharmaceuticals Inc. | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor |
US8501780B2 (en) | 2004-06-24 | 2013-08-06 | Glaxosmithkline Llc | Indazole carboxamides and their use |
WO2006005436A1 (de) * | 2004-07-10 | 2006-01-19 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur herstellung der enantiomeren formen von 2,3-diaminopropionsäurederivaten |
AU2005261977B2 (en) * | 2004-07-10 | 2010-11-04 | Sanofi-Aventis Deutschland Gmbh | Method for producing enantiomeric form of 2, 3-diaminopropionic acid derivatives |
US8053590B2 (en) | 2004-07-10 | 2011-11-08 | Sanofi-Aventis Deutschland Gmbh | Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives |
US7858796B2 (en) | 2004-09-21 | 2010-12-28 | Glaxo Group Limited | Chemical compounds |
WO2006076318A1 (en) * | 2005-01-12 | 2006-07-20 | Aventis Pharmaceuticals Inc. | Monopotassium salt of an ikb kinase inhibitor |
EP2226319A1 (de) | 2005-06-01 | 2010-09-08 | sanofi-aventis | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
JP2008542315A (ja) * | 2005-06-01 | 2008-11-27 | サノフィ−アベンティス | 2−(2−アミノ−ピリミジン−4−イル)−1h−インドール−5−カルボン酸誘導体の製造方法 |
US8546567B2 (en) | 2005-06-01 | 2013-10-01 | Sanofi | Method for producing 2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxylic acid derivatives |
JP2013121958A (ja) * | 2005-06-01 | 2013-06-20 | Sanofi | 2−(2−アミノ−ピリミジン−4−イル)−1h−インドール−5−カルボン酸誘導体の製造方法 |
US8232395B2 (en) | 2005-06-01 | 2012-07-31 | Sanofi | Method for producing 2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxylic acid derivatives |
WO2006128585A1 (de) * | 2005-06-01 | 2006-12-07 | Sanofi-Aventis | Verfahren zur herstellung von 2-(2-amino-pyrimidin-4-yl)-1h-indol-5-carbonsäure-derivaten |
US8354406B2 (en) | 2005-06-30 | 2013-01-15 | Glaxosmithkline Llc | Chemical compounds |
WO2007005534A2 (en) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
EP2266561A2 (de) | 2005-09-07 | 2010-12-29 | Merck Serono S.A. | IKK-Inhibitoren zur Behandlung von Endometriose |
WO2007043653A1 (ja) * | 2005-10-13 | 2007-04-19 | Taisho Pharmaceutical Co., Ltd. | ベンゾイミダゾール-5-カルボキサミド誘導体 |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US8372875B2 (en) | 2007-03-23 | 2013-02-12 | GlaxoSmithKline, LLC | Indole carboxamides as IKK2 inhibitors |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
US8071584B2 (en) | 2007-03-23 | 2011-12-06 | Glaxosmithkline Llc | Indole carboxamides as IKK2 inhibitors |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8501166B2 (en) | 2010-04-27 | 2013-08-06 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
AU2010351938B2 (en) * | 2010-04-27 | 2014-10-30 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
WO2011134140A1 (en) * | 2010-04-27 | 2011-11-03 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
RU2552999C2 (ru) * | 2010-04-27 | 2015-06-10 | Хатчисон Медифарма Лимитед | Соединения пиримидинилиндола |
JP2013525381A (ja) * | 2010-04-27 | 2013-06-20 | ハチソン メディファーマ リミテッド | ピリミジニルインドール化合物 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8877926B2 (en) | 2010-08-12 | 2014-11-04 | Sanofi | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives |
CN103209961A (zh) * | 2010-08-12 | 2013-07-17 | 赛诺菲 | 用于制备2,3-二氨基丙酸衍生物的对映异构体形式的方法 |
US9434696B2 (en) | 2010-08-12 | 2016-09-06 | Sanofi | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives |
WO2012019967A1 (en) | 2010-08-12 | 2012-02-16 | Sanofi | Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives |
US9089136B2 (en) | 2010-12-01 | 2015-07-28 | Sumitomo Chemical Company, Limited | Pyrimidine compound and use thereof for pest control |
WO2012074135A1 (en) * | 2010-12-01 | 2012-06-07 | Sumitomo Chemical Company, Limited | Pyrimidine compound and use for pest control thereof |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US11524951B2 (en) | 2011-07-27 | 2022-12-13 | Astrazeneca Ab | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
US10858336B2 (en) | 2011-07-27 | 2020-12-08 | Astazeneca Ab | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
US9416124B2 (en) | 2011-08-25 | 2016-08-16 | St. Jude Children's Research Hospital | Substituted 2-alkyl-1-OXO-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
WO2013027196A1 (en) * | 2011-08-25 | 2013-02-28 | St. Jude Children's Research Hospital | Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20140336211A1 (en) * | 2011-12-06 | 2014-11-13 | Sanofi | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-Indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl ] -amide |
US9067918B2 (en) | 2011-12-06 | 2015-06-30 | Sanofi | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl ]-amide |
RU2631320C2 (ru) * | 2011-12-06 | 2017-09-21 | Санофи | Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты |
WO2013083553A1 (en) | 2011-12-06 | 2013-06-13 | Sanofi | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
AU2012347393B2 (en) * | 2011-12-06 | 2017-06-08 | Sanofi | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
US9029334B2 (en) | 2013-03-29 | 2015-05-12 | Lifetree Biotech Co., Ltd. | Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative |
EP3184095A1 (de) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Verabreichungseinheiten die ein polymorph 1 von 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide beinhalten |
EP2805705A1 (de) | 2013-05-23 | 2014-11-26 | IP Gesellschaft für Management mbH | Verpackung enthaltend Verabreichungseinheiten von Natriumsalzen der (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-Propionsäure |
RU2687094C2 (ru) * | 2014-07-03 | 2019-05-07 | Санофи | [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амид 2-(2-метиламинопиримидин-4-ил)-1h-индол-5-карбоновой кислоты для применения в лечении связанной с остеоартритом боли |
AU2015283052B2 (en) * | 2014-07-03 | 2020-01-02 | Sanofi | 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid ((s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl)-amide for use in the treatment of pain associated to osteoarthritis |
WO2016001197A1 (en) * | 2014-07-03 | 2016-01-07 | Sanofi | 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis |
WO2021154902A1 (en) * | 2020-01-30 | 2021-08-05 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
CN115974849A (zh) * | 2022-12-28 | 2023-04-18 | 中国药科大学 | 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1530568B1 (de) | INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE | |
EP1261601B1 (de) | Substituierte indole zur modulierung von nfkb-aktivität | |
JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
EP1194425B1 (de) | Substituierte benzimidazole | |
US9242977B2 (en) | Trk-inhibiting compound | |
EP1531819B1 (de) | VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE | |
TW200307535A (en) | Therapeutic agent for cancer | |
WO2010057418A1 (zh) | 苯氧基嘧啶衍生物及其制备方法和用途 | |
JP2009514817A (ja) | 新規インドール含有ベータ−アゴニスト、それらの製造方法及び薬物としてのそれらの使用 | |
DE10006297A1 (de) | Substituierte Benzimidazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0104 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/00322 Country of ref document: ZA Ref document number: 200500322 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20050042A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2003000026 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001314 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003793685 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166785 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538296 Country of ref document: NZ Ref document number: 05013335 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004533319 Country of ref document: JP Ref document number: 374229 Country of ref document: PL Ref document number: 198/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038195437 Country of ref document: CN Ref document number: 1020057002707 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003263196 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2498559 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005107418 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500324 Country of ref document: VN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003793685 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002707 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500072 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: PI0313562 Country of ref document: BR |